Publication charges for this article were waived due to the ongoing pandemic of COVID-19.
WHO, 2020. Tuberculosis. Available at: https://www.who.int/news-room/fact-sheets/detail/tuberculosis. Accessed February 27, 2021.
Centers for Disease Control and Prevention, 2020. Tuberculosis. Global Health. Available at: https://www.cdc.gov/globalhealth/newsroom/topics/tb/index.html. Accessed February 27, 2021.
Piqueras AR, Marruecos L, Artigas A, Rodriguez C, 1987. Miliary tuberculosis and adult respiratory distress syndrome. Intensive Care Med 13: 175–182.
Mert A et al. 2017. Miliary tuberculosis: epidemiological and clinical analysis of large-case series from moderate to low tuberculosis endemic Country. Medicine 96.
Al Kuwari HM et al. 2020. Epidemiological investigation of the first 5685 cases of SARS-CoV-2 infection in Qatar, 28 February–18 April 2020. BMJ Open 10: 40428.
Moss AR, Hahn JA, Tulsky JP, Daley CL, Small PM, Hopewell PC, 2000. Tuberculosis in the homeless: a prospective study. Am J Crit Care Med 162. Available at: https://www.atsjournals.org/doi/full/10.1164/ajrccm.162.2.9910055. Accessed February 5, 2021.
Kim D, Quinn J, Pinsky B, Shah NH, Brown I, 2020. Rates of co-infection between SARS-CoV-2 and other respiratory pathogens. JAMA 323: 2085–2086.
Liu C et al. 2020. Severe COVID-19 cases with a history of active or latent tuberculosis. Int J Tuberc Lung Dis, doi: 10.5588/ijtld.20.0163.
Tadolini M et al. 2020. Active tuberculosis, sequelae and COVID-19 co-infection: first cohort of 49 cases. Eur Respir J 56, doi: 10.1183/13993003.01398-2020.
Stochino C, Villa S, Zucchi P, Parravicini P, Gori A, Raviglione MC, 2020. Clinical characteristics of COVID-19 and active tuberculosis co-infection in an Italian reference hospital. Eur Respir J 56: 2001708.
Yao Z et al. 2020. Three patients with COVID-19 and pulmonary tuberculosis, Wuhan, China, January–February 2020. Emerg Infect Dis 26, doi: 10.3201/eid2611.201536.
Tham SM, Lim WY, Lee CK, Loh J, Premkumar A, Yan B, Kee A, Chai L, Tambyah PA, Yan G, 2020. Four patients with COVID-19 and tuberculosis, Singapore, April–May 2020. Emerg Infect Dis 26, doi: 10.3201/eid2611.202752.
Faqihi F, Alharthy A, Noor AF, Balshi A, Balhamar A, Karakitsos D, 2020. COVID-19 in a patient with active tuberculosis: a rare case-report. Respir Med Case Rep 31: 101146.
Diao B et al. 2020. Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19). medRxiv, doi: 10.1101/2020.02.18.20024364.
Foreman TW et al. 2016. CD4+ T-cell-independent mechanisms suppress reactivation of latent tuberculosis in a macaque model of HIV coinfection. Proc Natl Acad Sci USA 113: E5636–E5644.
Gautret P et al. 2020. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 56: 105949.
Chen J et al. 2020. A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19. Zhejiang Da Xue Xue Bao Yi Xue Ban 49: 215–219.
Furtado RHM et al. 2020. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. Lancet 396: 959–967.
RECOVERY Collaborative Group, 2020. Effect of hydroxychloroquine in hospitalized patients with COVID-19. N Engl J Med 383: 2030–2040.